Infusion pump maker KORU Medical Q3 revenue jumps, raises 2025 rev guidance

Overview

• KORU Medical Q3 revenue grows 27% yr/yr, driven by strong international sales

• Company improves Q3 net loss by 51% yr/yr, adjusted EBITDA turns positive

• KORU raises full-year 2025 revenue guidance to $40.5 - $41.0 mln

Outlook

• KORU Medical raises full-year 2025 revenue guidance to $40.5 - $41.0 mln, from prior range of $39.5 - $40.5 mln

• Company reiterates full-year 2025 gross margin guidance of 61% - 63%

• Company expects positive cash flow from operations for full year 2025

Result Drivers

• INTERNATIONAL SALES - Strong international sales driven by strategic market supply and new patient starts

• DOMESTIC SALES DECLINE - Domestic sales impacted by distributor inventory adjustments

• PHARMA COLLABORATIONS - New pharmaceutical collaborations expected to expand patient reach

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for KORU Medical Systems Inc is $6.00, about 37.8% above its November 11 closing price of $3.73

Press Release: ID:nBw7Zn4B3a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)